A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer

René W.M. Underberg, John R. van Sörnsen de Koste, Frank J. Lagerwaard, Andrew Vincent, Ben J. Slotman, Suresh Senan

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Respiration-gated radiotherapy can permit the irradiation of smaller target volumes. 4DCT scans performed for routine treatment were retrospectively analyzed to establish the benefits of gating in stage III non-small cell lung cancer (NSCLC). Materials and methods: Gross tumor volumes (GTVs) were contoured in all 10 respiratory phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment planning was performed using different planning target volumes (PTVs), namely: (i) PTVroutine, derived from a single GTV plus 'conventional' margins; (ii) PTVall phases incorporating all 3D mobility captured by the 4DCT; (iii) PTVgating, incorporating residual 3D mobility in 3-4 phases at end-expiration. Mixed effect models were constructed in order to estimate the reductions in risk of lung toxicity for the different PTVs. Results: Individual GTVs ranged from 41.5 - 235.0 cm3. With patient-specific mobility data (PTVall phases), smaller PTVs were derived than when 'standard' conventional margins were used (p < 0.001). The average residual 3D tumor mobility within the gating window was 4.0 ± 3.5 mm, which was 5.5 mm less than non-gated tumor mobility (p < 0.001). The reductions in mean lung dose were 9.7% and 4.9%, respectively, for PTVall phases versus PTVroutine, and PTVgating versus PTVall phases. The corresponding reductions in V20 were 9.8% and 7.0%, respectively. Dosimetric gains were smaller for primary tumors of the upper lobe versus other locations (p = 0.02). Respiratory gating also reduced the risks of radiation-induced esophagitis. Conclusion: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity but the benefits are particularly evident for tumors of the middle and lower lobes.

LanguageEnglish
Article number8
JournalRadiation Oncology
Volume1
Issue number1
DOIs
Publication statusPublished - 31 Mar 2006

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Underberg, R. W. M., van Sörnsen de Koste, J. R., Lagerwaard, F. J., Vincent, A., Slotman, B. J., & Senan, S. (2006). A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiation Oncology, 1(1), [8]. https://doi.org/10.1186/1748-717X-1-8
Underberg, René W.M. ; van Sörnsen de Koste, John R. ; Lagerwaard, Frank J. ; Vincent, Andrew ; Slotman, Ben J. ; Senan, Suresh. / A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. In: Radiation Oncology. 2006 ; Vol. 1, No. 1.
@article{46adc696386a429eb71879bef73945d4,
title = "A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer",
abstract = "Background: Respiration-gated radiotherapy can permit the irradiation of smaller target volumes. 4DCT scans performed for routine treatment were retrospectively analyzed to establish the benefits of gating in stage III non-small cell lung cancer (NSCLC). Materials and methods: Gross tumor volumes (GTVs) were contoured in all 10 respiratory phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment planning was performed using different planning target volumes (PTVs), namely: (i) PTVroutine, derived from a single GTV plus 'conventional' margins; (ii) PTVall phases incorporating all 3D mobility captured by the 4DCT; (iii) PTVgating, incorporating residual 3D mobility in 3-4 phases at end-expiration. Mixed effect models were constructed in order to estimate the reductions in risk of lung toxicity for the different PTVs. Results: Individual GTVs ranged from 41.5 - 235.0 cm3. With patient-specific mobility data (PTVall phases), smaller PTVs were derived than when 'standard' conventional margins were used (p < 0.001). The average residual 3D tumor mobility within the gating window was 4.0 ± 3.5 mm, which was 5.5 mm less than non-gated tumor mobility (p < 0.001). The reductions in mean lung dose were 9.7{\%} and 4.9{\%}, respectively, for PTVall phases versus PTVroutine, and PTVgating versus PTVall phases. The corresponding reductions in V20 were 9.8{\%} and 7.0{\%}, respectively. Dosimetric gains were smaller for primary tumors of the upper lobe versus other locations (p = 0.02). Respiratory gating also reduced the risks of radiation-induced esophagitis. Conclusion: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity but the benefits are particularly evident for tumors of the middle and lower lobes.",
author = "Underberg, {Ren{\'e} W.M.} and {van S{\"o}rnsen de Koste}, {John R.} and Lagerwaard, {Frank J.} and Andrew Vincent and Slotman, {Ben J.} and Suresh Senan",
year = "2006",
month = "3",
day = "31",
doi = "10.1186/1748-717X-1-8",
language = "English",
volume = "1",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

Underberg, RWM, van Sörnsen de Koste, JR, Lagerwaard, FJ, Vincent, A, Slotman, BJ & Senan, S 2006, 'A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer', Radiation Oncology, vol. 1, no. 1, 8. https://doi.org/10.1186/1748-717X-1-8

A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. / Underberg, René W.M.; van Sörnsen de Koste, John R.; Lagerwaard, Frank J.; Vincent, Andrew; Slotman, Ben J.; Senan, Suresh.

In: Radiation Oncology, Vol. 1, No. 1, 8, 31.03.2006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer

AU - Underberg, René W.M.

AU - van Sörnsen de Koste, John R.

AU - Lagerwaard, Frank J.

AU - Vincent, Andrew

AU - Slotman, Ben J.

AU - Senan, Suresh

PY - 2006/3/31

Y1 - 2006/3/31

N2 - Background: Respiration-gated radiotherapy can permit the irradiation of smaller target volumes. 4DCT scans performed for routine treatment were retrospectively analyzed to establish the benefits of gating in stage III non-small cell lung cancer (NSCLC). Materials and methods: Gross tumor volumes (GTVs) were contoured in all 10 respiratory phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment planning was performed using different planning target volumes (PTVs), namely: (i) PTVroutine, derived from a single GTV plus 'conventional' margins; (ii) PTVall phases incorporating all 3D mobility captured by the 4DCT; (iii) PTVgating, incorporating residual 3D mobility in 3-4 phases at end-expiration. Mixed effect models were constructed in order to estimate the reductions in risk of lung toxicity for the different PTVs. Results: Individual GTVs ranged from 41.5 - 235.0 cm3. With patient-specific mobility data (PTVall phases), smaller PTVs were derived than when 'standard' conventional margins were used (p < 0.001). The average residual 3D tumor mobility within the gating window was 4.0 ± 3.5 mm, which was 5.5 mm less than non-gated tumor mobility (p < 0.001). The reductions in mean lung dose were 9.7% and 4.9%, respectively, for PTVall phases versus PTVroutine, and PTVgating versus PTVall phases. The corresponding reductions in V20 were 9.8% and 7.0%, respectively. Dosimetric gains were smaller for primary tumors of the upper lobe versus other locations (p = 0.02). Respiratory gating also reduced the risks of radiation-induced esophagitis. Conclusion: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity but the benefits are particularly evident for tumors of the middle and lower lobes.

AB - Background: Respiration-gated radiotherapy can permit the irradiation of smaller target volumes. 4DCT scans performed for routine treatment were retrospectively analyzed to establish the benefits of gating in stage III non-small cell lung cancer (NSCLC). Materials and methods: Gross tumor volumes (GTVs) were contoured in all 10 respiratory phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment planning was performed using different planning target volumes (PTVs), namely: (i) PTVroutine, derived from a single GTV plus 'conventional' margins; (ii) PTVall phases incorporating all 3D mobility captured by the 4DCT; (iii) PTVgating, incorporating residual 3D mobility in 3-4 phases at end-expiration. Mixed effect models were constructed in order to estimate the reductions in risk of lung toxicity for the different PTVs. Results: Individual GTVs ranged from 41.5 - 235.0 cm3. With patient-specific mobility data (PTVall phases), smaller PTVs were derived than when 'standard' conventional margins were used (p < 0.001). The average residual 3D tumor mobility within the gating window was 4.0 ± 3.5 mm, which was 5.5 mm less than non-gated tumor mobility (p < 0.001). The reductions in mean lung dose were 9.7% and 4.9%, respectively, for PTVall phases versus PTVroutine, and PTVgating versus PTVall phases. The corresponding reductions in V20 were 9.8% and 7.0%, respectively. Dosimetric gains were smaller for primary tumors of the upper lobe versus other locations (p = 0.02). Respiratory gating also reduced the risks of radiation-induced esophagitis. Conclusion: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity but the benefits are particularly evident for tumors of the middle and lower lobes.

UR - http://www.scopus.com/inward/record.url?scp=33846239895&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-1-8

DO - 10.1186/1748-717X-1-8

M3 - Article

VL - 1

JO - Radiation Oncology

T2 - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 8

ER -